Published in Clin Cancer Res on July 06, 2012
Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther (2013) 1.96
The mutational landscape of adenoid cystic carcinoma. Nat Genet (2013) 1.83
Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death Dis (2014) 1.22
Tumor evolution and intratumor heterogeneity of an oropharyngeal squamous cell carcinoma revealed by whole-genome sequencing. Neoplasia (2013) 0.99
Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications. Eur Arch Otorhinolaryngol (2013) 0.91
Regulated proteolysis of NOTCH2 and NOTCH3 receptors by ADAM10 and presenilins. Mol Cell Biol (2014) 0.91
Inhibition of notch signaling in combination with Paclitaxel reduces platinum-resistant ovarian tumor growth. Front Oncol (2014) 0.83
Oncogenes associated with drug resistance in ovarian cancer. J Cancer Res Clin Oncol (2014) 0.82
Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features. Cancer Prev Res (Phila) (2015) 0.81
Notch pathway activation is essential for maintenance of stem-like cells in early tongue cancer. Oncotarget (2016) 0.80
The antioxidant paradox: what are antioxidants and how should they be used in a therapeutic context for cancer. Future Med Chem (2014) 0.79
Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer. Int J Biol Sci (2016) 0.79
Human NOTCH2 Is Resistant to Ligand-independent Activation by Metalloprotease Adam17. J Biol Chem (2015) 0.79
Canonical Notch signalling is inactive in urothelial carcinoma. BMC Cancer (2014) 0.78
Nrf2 and Notch Signaling in Lung Cancer: Near the Crossroad. Oxid Med Cell Longev (2016) 0.78
Overexpression of Notch3 and pS6 Is Associated with Poor Prognosis in Human Ovarian Epithelial Cancer. Mediators Inflamm (2016) 0.77
Suppression of radiation-induced migration of non-small cell lung cancer through inhibition of Nrf2-Notch Axis. Oncotarget (2017) 0.75
Notch 2 signaling contributes to cell growth, anti-apoptosis and metastasis in laryngeal squamous cell carcinoma. Mol Med Rep (2016) 0.75
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
The canonical Notch signaling pathway: unfolding the activation mechanism. Cell (2009) 14.72
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell (1991) 10.06
Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature (2007) 9.09
The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer (2003) 4.75
High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res (2005) 4.61
Notch signaling: the core pathway and its posttranslational regulation. Dev Cell (2009) 4.49
Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer (2011) 4.12
Chronic DLL4 blockade induces vascular neoplasms. Nature (2010) 3.14
Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A (2011) 3.10
Notch promotes radioresistance of glioma stem cells. Stem Cells (2010) 3.07
The multifaceted role of Notch in cancer. Curr Opin Genet Dev (2006) 3.07
Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med (2011) 2.40
The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J Biol Chem (2003) 2.22
Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist (2007) 1.96
More complicated than it looks: assembly of Notch pathway transcription complexes. Oncogene (2008) 1.48
Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica (2009) 1.48
A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res (2008) 1.46
Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer (2010) 1.42
The Abruptex domain of Notch regulates negative interactions between Notch, its ligands and Fringe. Development (2000) 1.41
The C-terminal PDZ-ligand of JAGGED1 is essential for cellular transformation. J Biol Chem (2002) 1.40
Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol (2011) 1.39
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer (2010) 1.33
Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma. Cancer Res (2011) 1.28
Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method. Cancer (2010) 1.15
Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer. Cancer Res (2010) 1.13
Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery (2008) 1.08
Somatic mutations in the Notch, NF-KB, PIK3CA, and Hedgehog pathways in human breast cancers. Genes Chromosomes Cancer (2012) 1.06
A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist (2011) 1.05
A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer (2012) 1.05
Notch signaling inhibits growth of the human lung adenocarcinoma cell line A549. Oncol Rep (2007) 1.05
Association of high levels of Jagged-1 and Notch-1 expression with poor prognosis in head and neck cancer. Ann Surg Oncol (2010) 1.04
Growth suppression induced by Notch1 activation involves Wnt-beta-catenin down-regulation in human tongue carcinoma cells. Biol Cell (2006) 1.03
High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097. Mol Oncol (2011) 1.02
Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer. Ann Surg Oncol (2010) 0.97
Discovery of a novel series of Notch-sparing gamma-secretase inhibitors. Bioorg Med Chem Lett (2008) 0.87
Activation of Notch signaling in human tongue carcinoma. J Oral Pathol Med (2010) 0.87
Development and validation of sensitive and selective LC-MS/MS methods for the determination of BMS-708163, a gamma-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.80
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol (2006) 3.67
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res (2006) 3.28
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck (2007) 2.49
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov (2012) 2.31
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov (2013) 2.29
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res (2005) 2.28
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother (2009) 2.25
STAT-mediated EGFR signaling in cancer. J Cell Biochem (2007) 2.05
TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Res (2012) 1.98
STAT3 signaling: anticancer strategies and challenges. Mol Interv (2011) 1.95
Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res (2012) 1.89
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.63
The impact of health insurance status on the survival of patients with head and neck cancer. Cancer (2010) 1.58
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res (2009) 1.57
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila) (2013) 1.56
Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene (2005) 1.56
Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci (2008) 1.50
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck (2010) 1.45
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA (2007) 1.41
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res (2004) 1.39
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol (2010) 1.37
Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res (2011) 1.34
Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis (2009) 1.30
Selective jejunal manipulation causes postoperative pan-enteric inflammation and dysmotility. Gastroenterology (2004) 1.28
Understanding the presence and function of erythropoietin receptors on cancer cells. J Clin Oncol (2006) 1.25
Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs (2010) 1.25
Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res (2010) 1.25
MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. Carcinogenesis (2010) 1.24
Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells. FASEB J (2008) 1.21
Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res (2007) 1.20
Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res (2010) 1.18
Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys (2009) 1.17
New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res (2010) 1.17
Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res (2010) 1.17
ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res (2008) 1.17
Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol (2008) 1.16
Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res (2011) 1.15
Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther (2008) 1.15
c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clin Cancer Res (2012) 1.15
Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: the University of Pittsburgh experience. Laryngoscope (2010) 1.14
Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene (2005) 1.13
ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol (2009) 1.13
Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth. Mol Cancer Ther (2008) 1.12
Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol (2008) 1.12
Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res (2012) 1.12
Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prev Res (Phila) (2010) 1.10
Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. Exp Cell Res (2007) 1.09
Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck (2008) 1.08
Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Mol Cancer Ther (2009) 1.08
MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck. Cancer (2010) 1.07
Molecular mediators of metastasis in head and neck squamous cell carcinoma. Head Neck (2005) 1.07
Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol (2009) 1.04
Head and neck cancer: recent advances and new standards of care. J Clin Oncol (2006) 1.02
Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. Laryngoscope (2005) 1.02
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res (2013) 1.02
Nucleic acid-based approaches to STAT inhibition. JAKSTAT (2012) 1.02
EGFR tyrosine kinase inhibition induces autophagy in cancer cells. Cancer Biol Ther (2012) 1.01
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A (2014) 1.01
Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes. Clin Cancer Res (2008) 1.00
Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin Radiat Oncol (2009) 1.00
Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells. Neoplasia (2007) 1.00
Critical analysis of the potential for targeting STAT3 in human malignancy. Onco Targets Ther (2013) 0.99
Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs (2010) 0.99
Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection. Mol Cancer Res (2014) 0.99
Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma. Head Neck Pathol (2013) 0.97
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest (2014) 0.97
Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncol (2011) 0.97
The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma. Mutat Res (2013) 0.95
The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. Am J Clin Oncol (2011) 0.94
Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clin Cancer Res (2012) 0.94
XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clin Cancer Res (2011) 0.93
Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab. Clin Cancer Res (2011) 0.93
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy (2012) 0.92
Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. Neoplasia (2012) 0.92
Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells. J Cell Biochem (2008) 0.92
Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clin Cancer Res (2008) 0.92
High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev Technol (2013) 0.91
Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr (2014) 0.90
Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. Clin Cancer Res (2012) 0.90
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. Cancer Biol Ther (2012) 0.90
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J Clin Invest (2015) 0.90
Association of the EGFR intron 1 CA repeat length with lung cancer risk. Mol Carcinog (2007) 0.89
Mutation and polymorphism in the EGFR-TK domain associated with lung cancer. J Thorac Oncol (2006) 0.89
PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. BMC Cancer (2013) 0.89
Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer. Mol Cancer Ther (2012) 0.89
Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract. Mol Carcinog (2005) 0.88
The molecular pathogenesis of head and neck cancer. Cancer Biol Ther (2010) 0.87
Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas. Mol Cancer Res (2008) 0.87
Prognostic biomarkers in head and neck cancer. Clin Cancer Res (2006) 0.87
Importance of molecular analysis in detecting cervical lymph node metastasis in head and neck squamous cell carcinoma. Head Neck (2006) 0.87
Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert Rev Anticancer Ther (2003) 0.87
PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. J Clin Invest (2015) 0.86
Molecular changes in the multistage pathogenesis of head and neck cancer. Cancer Biomark (2010) 0.86
Childhood passive smoke exposure is associated with adult head and neck cancer. Cancer Epidemiol (2013) 0.86
Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck. Clin Med Insights Ther (2013) 0.85
Lipopolysaccharide preconditioning and cross-tolerance: the induction of protective mechanisms for rat intestinal ileus. Gastroenterology (2002) 0.85
Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer. J Proteome Res (2010) 0.85